| 朝陽科技大學 |
2022-03-08 |
振興政策對民眾消費行為影響與探討－以振興五倍券為例
|
高沛琪;吳承洧;林珊亦;游啟賢 |
| 朝陽科技大學 |
2022-03-08 |
人工智能與管理會計：神經網路模型之應用
|
黃品淯;黃于軒;溫淳如;林玉婷;林雨潔 |
| 朝陽科技大學 |
2022-03-08 |
我國銀行推動綠色金融政策之事件宣告效果
|
許育誠;劉香蓮;陳翰彰;廖柏誌;賴沂汭;邱子馨 |
| 朝陽科技大學 |
2022-03-08 |
會計師審計風險調控策略
|
林郁儒;潘昱宏;楊美綸;賴霈諭;涂瑋傑 |
| 淡江大學 |
2022-03-08 |
Measuring the cosmological density field twice: A novel test of dark energy using the CMB quadrupole
|
Liu, Guo-chin |
| 淡江大學 |
2022-03-08 |
111年臺灣學術資源影響力分析報告
|
王豐瑋;王宏德;吳柏岳;梁鴻栩 |
| 國立成功大學 |
2022-03-08 |
病理切片影像的脂滴分割方法與電腦程式產品
|
詹寶珠;CHUNG, PAU-CHOO;蔡弘文;TSAI, HUNG-WEN;吳俊忻;WU, JYUN-SIN;林于暄;LIN, YU-HSUAN;鄭國順;CHENG, KUO-SHENG |
| 國家衛生研究院 |
2022-03-08 |
Compositions and methods for enhancement of immune responses
|
Chen, HW;Leng, CH;Liu, SJ |
| 國家衛生研究院 |
2022-03-08 |
Opioid receptor modulators and use thereof
|
Ueng, SH;Yeh, SH;Loh, H;Chao, YS |
| 臺大學術典藏 |
2022-03-08T01:40:10Z |
導讀：於歷史書寫中思索命運的無常
|
洪瑟君; 洪瑟君; SE-CHUN HUNG |
| 臺大學術典藏 |
2022-03-08T01:52:29Z |
Evidence for human-environment interactions as the driver for the abandonment of long-term Neolithic occupation at the Wansan site(NE Taiwan) around the 7th century BCE
|
CHIANG, Chih-Hua |
| 臺大學術典藏 |
2022-03-08T03:43:58Z |
Competing Risk Analysis of Outcomes of Unresectable Pancreatic Cancer Patients Undergoing Definitive Radiotherapy
|
Chen Y.-L.; Tsai C.-L.; Cheng J.C.-H.; Wang C.-W.; SHIH-HUNG YANG; Tien Y.-W.; Kuo S.-H. |
| 臺大學術典藏 |
2022-03-08T03:43:59Z |
Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-�eB-related signaling
|
Kuo S.-H.; SHIH-HUNG YANG; Wei M.-F.; Lee H.-W.; Tien Y.-W.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2022-03-08T03:43:59Z |
Preoperative 2-[18F]FDG PET-CT aids in the prognostic stratification for patients with primary ampullary carcinoma
|
Chuang P.-J.; Wang H.-P.; Lin Y.-J.; Chen C.-C.; Tien Y.-W.; Hsieh M.-S.; SHIH-HUNG YANG; Yen R.-F.; Ko C.-L.; Wu Y.-W.; Cheng M.-F. |
| 臺大學術典藏 |
2022-03-08T03:44:00Z |
Metabolic alterations in pancreatic cancer detected by in vivo1h-mr spectroscopy: Correlation with normal pancreas, pet metabolic activity, clinical stages, and survival outcome
|
Chang C.-K.; Shih T.T.-F.; Tien Y.-W.; Chang M.-C.; Chang Y.-T.; SHIH-HUNG YANG; Cheng M.-F.; Chen B.-B. |
| 臺大學術典藏 |
2022-03-08T03:44:00Z |
C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin �\v
|
Kuo T.-C.; Wu M.-H.; SHIH-HUNG YANG; Chen S.-T.; Hsu T.-W.; Jhuang J.-Y.; Liao Y.-Y.; Tien Y.-W.; Huang M.-C. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study
|
Su Y.-Y.; Chiu Y.-F.; Li C.-P.; SHIH-HUNG YANG; Lin J.; Lin S.-J.; Chang P.-Y.; Chiang N.-J.; Shan Y.-S.; Ch��ang H.-J.; Chen L.-T. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients�� experience within a population-based study
|
Chiu T.-J.; Su Y.-Y.; SHIH-HUNG YANG; Li C.-P.; Bai L.-Y.; Chiang N.-J.; Chuang S.-C.; Shan Y.-S.; Chan D.-C.; Chen L.-T.; Yen C.-J.; Peng C.-M.; Chen Y.-Y.; Chen J.-S.; Chou W.-C. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
|
SHIH-HUNG YANG; Lu L.-C.; Kao H.-F.; Chen B.-B.; Kuo T.-C.; Kuo S.-H.; Tien Y.-W.; Bai L.-Y.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.; Chen M.-H.; SHIH-HUNG YANG; Hsu C.; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2022-03-08T03:44:02Z |
S-1�Vassociated hypertriglyceridemia in a patient with pancreatic adenocarcinoma
|
Chen H.-W.; Kuo H.-Y.; Chen B.-B.; Tien Y.-W.; Kuo S.-H.; SHIH-HUNG YANG |
| 臺大學術典藏 |
2022-03-08T03:44:02Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; SHIH-HUNG YANG; Hsiao H.-H.; Shen W.-C.; Hsu C.; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2022-03-08T03:44:02Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
SHIH-HUNG YANG; Guo J.-C.; Hsu C.; Kuo S.-H.; Tien Y.-W.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2022-03-08T03:44:03Z |
Postoperative imaging and tumor marker surveillance in resected pancreatic cancer
|
Wu H.; Guo J.-C.; SHIH-HUNG YANG; Tien Y.-W.; Kuo S.-H. |
| 臺大學術典藏 |
2022-03-08T03:44:03Z |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
SHIH-HUNG YANG; Shao Y.-Y.; Lin C.-C.; Kuo S.-H.; Cheng A.-L.; Yeh K.-H. |
